Agios Pharmaceuticals, Inc. (AGIO)

47.75 +1.01 (+2.16%) At close: 4:00PM EDT

Agios Pharmaceuticals, Inc.

88 Sidney Street
2nd Floor
Cambridge, MA 02139-4169
United States
617 649 8600
http://www.agios.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 562

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jacqualyn A. Fouse	CEO & Director	1.27M	N/A	1961
Mr. Jonathan Biller J.D.	CFO and Head of Legal & Corp. Affairs	769.33k	N/A	1964
Dr. Bruce Car Ph.D.	Chief Scientific Officer	894.8k	N/A	1962
Dr. Christopher J. Bowden M.D.	Strategic Advisor	767.55k	825.41k	1961
Dr. Lewis Clayton Cantley	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1949
Dr. Tak Wah Mak	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1946
Dr. Craig B. Thompson	Co-Founder & Chairman of Scientific Advisory Board	N/A	N/A	1953
Dr. Shin-San Su Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1956
Mr. T. J. Washburn Jr.	Principal Accounting Officer	N/A	N/A	1981
Dr. Clive Patience	Exec. VP of Technical Operations	N/A	N/A	1964

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.

Corporate governance

Agios Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 July 2021 is 6. The pillar scores are Audit: 2; Board: 4; Shareholder rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.